Amira Medical Technologies Inc

XORTX Therapeutics Inc, based in Calgary, AB, is a clinical pharmaceutical company focused on developing innovative therapies aimed at improving the quality of life for patients suffering from gout and progressive kidney diseases. The company is advancing several programs, including XRx026 for gout and XRx008 for Autosomal Dominant Polycystic Kidney Disease, which address issues related to aberrant purine metabolism and high uric acid levels. With a commitment to redefining drug development through strategic collaborations, XORTX is also exploring treatments for conditions related to coronavirus infections and Type 2 Diabetic Nephropathy. Their pipeline reflects a dedication to creating first-in-class uric acid lowering agents to manage chronic kidney diseases effectively. Generated from the website

The Board of Governors at the University of Calgary oversees the management and operations of the university's business and affairs, ensuring that activities align with its mandate and strategic direction. This governance body is responsible for the effective use of financial and human resources while managing institutional risks, primarily through oversight of the President and senior officers. Operating under the Alberta Post-Secondary Learning Act, the Board shares governance responsibilities with the General Faculties Council and the Executive Leadership Team. The University of Calgary acknowledges its location on traditional territories and is committed to fostering a collaborative and respectful learning environment. Generated from the website